TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03034915
Drug: Salmeterol 50 mcg via DISKUS
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Study: NCT03038503
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: after defined refractory shock (need NE\>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)
Study: NCT03038503
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: after defined refractory shock (need NE\>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
Study: NCT00162331
Drug: Technetium Tc99m Sestamibi
Normalized name: TECHNETIUM TC-99M SESTAMIBI 1 mg in 10 mL INTRAVENOUS INJECTION [Kit for the Preparation of Technetium Tc99m Sestamibi]
DrugBank: Technetium Tc-99m sestamibi (DB09161)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00243256
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04189900
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
Study: NCT00534560
Drug: Tonabersat
Normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
Study: NCT00534560
Drug: Tonabersat
Normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
Study: NCT02781415
Drug: Morphine Titration
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal.
Study: NCT00322751
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
Study: NCT00424762
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 months of treatment of blinded study drug
Study: NCT00242190
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00242190
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00246012
Drug: Intetumumab
Normalized name: Intetumumab
DrugBank: Intetumumab (DB12701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
Study: NCT00246012
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
Study: NCT04364789
Drug: TT-00920
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT00853827
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg
Study: NCT00520208
Drug: Tamibarotene
Normalized name: Tamibarotene
DrugBank: Tamibarotene (DB04942)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
Study: NCT02705352
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment medication
Study: NCT03216668
Drug: TONKA
Normalized name: Tonka bean camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally twice a day, 2 tablets each time, for 6 weeks.
Study: NCT03216668
Drug: LEGALON
DrugBank: Silibinin (DB09298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally three times a day, two tablets each time, for 6 weeks
Study: NCT02252588
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Rinse
Study: NCT01696370
Drug: Trimetazidine
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 20mg three times per day for 3 months
Study: NCT01391663
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
Study: NCT01391663
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
Study: NCT01391663
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
Study: NCT01125982
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
Study: NCT01125982
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
Study: NCT00978237
Drug: EFV
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one pill QD VO.
Study: NCT00947596
Drug: atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dry powder for inhalation
Study: NCT00947596
Drug: atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular injection
Study: NCT03564613
Drug: DTG
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects with DTG exposure during any trimester will be included
Study: NCT00250341
Drug: QVAR
Normalized name: Qvar
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mcg
Study: NCT00250341
Drug: Advair
Normalized name: Advair
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 250/50 mcg
Study: NCT01950403
Drug: linaclotide acetate
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00241722
Drug: Alvimopan
Normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02354534
Drug: Artesunate Suppositories
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03965013
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine given at a fixed dose level of 0.5 U/kg
Study: NCT01833559
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
Study: NCT01302353
Drug: Emulsified Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02481297
Drug: Lirilumab
Normalized name: Lirilumab
DrugBank: Lirilumab (DB11754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg by vein given on Day 1 of each 28 day cycle.
Study: NCT02481297
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
Study: NCT02618317
Drug: Trissodium Citrate 30%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
Study: NCT04339816
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally or into nasogastric tube for 5 days
Study: NCT02273661
Drug: Liposomal amphotericin B (Ambisome®)
Normalized name: amphotericin B liposomal Injection [AmBisome]
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
Study: NCT03857334
Drug: Injection of cortivazol : Altim®
DrugBank: Cortivazol (DB13003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids
Study: NCT03097016
Drug: CC-122
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
Study: NCT01716949
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m\^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
Study: NCT04981379
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
Study: NCT04981379
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo \[Hydroxychloroquine (200 mg)\], as two tablets per day for 5-day interval.
Study: NCT04981379
Drug: Favipiravir + Hydroxychloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
Study: NCT01716949
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/m\^2/d as 2-hour bolus infusion on d2, 9, 23, 30
Study: NCT00786318
Drug: ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ziprasidone 20mg IM
Study: NCT01787240
Drug: Escitalopram 10mg
Normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00116623
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02033018
Drug: Aflibercept Injection
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept intravitreal injection
Study: NCT02523391
Drug: TA-8995
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT02523391
Drug: TA-8995
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02504489
Drug: Docetaxel + Plinabulin (DP)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
Study: NCT02504489
Drug: Docetaxel (D)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 IV
Study: NCT04485156
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg
Study: NCT04485156
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-30mg/kg
Study: NCT04485156
Drug: Ethambutol
Normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-20mg/kg
Study: NCT00137293
Drug: 0.9% Sodium Chloride, USP
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04485156
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/kg
Study: NCT01194154
Drug: Methoxy polyethylene glycol-epoetin beta
Normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
Study: NCT01407289
Drug: Insulin Aspart, Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
Study: NCT00295542
Drug: beta blockers (including nebivolol, atenolol, carvedilol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at awakening versus bedtime
Study: NCT03219645
Drug: Ginkgo Diterpene Lactone Meglumine Injection
Normalized name: citronellene lactone
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
Study: NCT00295542
Drug: diuretics (torasemide, indapamide, HTCZ) and doxazosin
Normalized name: Indapamide
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment at awakening versus bedtime
Study: NCT02286921
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
Study: NCT00878722
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03394118
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
Study: NCT00115544
Drug: Stanate
Normalized name: 3-alpha,7-alpha-dihydroxy-5-beta-cholestanate--CoA ligase
DrugBank: Stannsoporfin (DB04912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
Study: NCT02286921
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
Study: NCT01962467
Drug: FF
Normalized name: MFF
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
Study: NCT01962467
Drug: LEV
Normalized name: Aleve
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
Study: NCT03369704
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
Study: NCT03674294
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant is manufactured by Merck \& Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
Study: NCT03674294
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
Study: NCT02286921
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
Study: NCT02733445
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02733445
Drug: nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00795704
Drug: Mulberry Leaf Extract
Normalized name: mulberry pollen extract
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
Study: NCT03674294
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
Study: NCT04347954
Drug: Povidone-Iodine 2%
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
Study: NCT04347954
Drug: Povidone-Iodine 0.5%
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
Study: NCT03491696
Drug: Metyrapone
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
Study: NCT00212784
Drug: asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
Study: NCT00212784
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily